Press Releases April 6, 2026 08:00 PM

LeMaitre to Present at the 25th Annual Needham Virtual Healthcare Conference

LeMaitre Vascular to Present at Needham Virtual Healthcare Conference

By Hana Yamamoto LMAT
LeMaitre to Present at the 25th Annual Needham Virtual Healthcare Conference
LMAT

LeMaitre Vascular, Inc., a developer and manufacturer of vascular devices for peripheral vascular disease treatment, announced its upcoming management presentation at the 25th Annual Needham Virtual Healthcare Conference scheduled for April 16, 2025.

Key Points

  • LeMaitre specializes in devices and implants for peripheral vascular disease affecting over 200 million worldwide.
  • The company targets vascular surgeons with its disposable and implantable vascular devices.
  • The management team will present at a significant healthcare investment conference, indicating efforts to engage with investors and the healthcare sector.

BURLINGTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2025, at 2:15 PM EDT.

About LeMaitre

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com.


Risks

  • Peripheral vascular disease treatment market is competitive, posing challenges for market share growth.
  • Dependence on vascular surgeons as core customers may limit diversification opportunities.
  • The impact of future healthcare regulations and reimbursement policies may affect sales and profitability.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026